Navigation Links
Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure
Date:12/15/2009

MONT-SAINT-GUIBERT, Belgium, December 15 /PRNewswire/ --

- 45 Patients Enrolled in Study Designed to Evaluate the Ability of Cardiopoietic Cells to Restore Cardiac Function

Cardio3 BioSciences, a leading Belgian biotechnology company specialising in cell-based therapies for the treatment of cardiovascular diseases, announced today that it has completed, two months ahead of schedule, enrolment in the first stage of its pivotal Phase II/III trial of C-Cure, a unique stem cell therapy for heart failure. Forty-five patients have now enrolled in the study which is being conducted at centres in Belgium and Serbia. The C-Cure trial will ultimately enroll 240 patients making it one of the largest randomized trials in regenerative therapies for heart failure.

C-Cure is produced by taking a patient's own bone marrow cells and, through a proprietary process, differentiating them into cardiopoietic cells that can regenerate damaged heart muscle. The cardiopoietic cells are injected into the heart of a patient with heart failure where they are designed to behave identically to those cells lost in heart failure without carrying the risk of rejection, something that has not been achieved with previous cell therapies for this indication. C-Cure is the outcome of multiple years of research conducted at Mayo Clinic (Rochester, Minnesota, USA) and at the Cardiovascular Center in Aalst (Aalst, Belgium).

Safety data from this stage of the trial is expected to be available in May 2010. The second stage, which will recruit 195 further patients is expected to start in the third quarter of 2010 and involve further sites in Europe and in the United States. The trial design is a randomized, prospective, multi-center trial, to evaluate the safety and efficacy of C-Cure beyond optimal clinical care in patients with heart failure. The trial will also evaluate socio-economic implications of therapy.

Dr Christian Homsy, CEO of Cardio3 BioSciences said: "We believe C-Cure holds the promise for a treatment that could fundamentally change the future of heart failure patients, one of the world's greatest medical needs. The fact that we have been able to fully enroll the first stage of the trial two months ahead of schedule speaks to the interest physicians have in this potential new therapy and brings us a step nearer a new treatment for a condition where at present current therapy does not address the underlying cause of the disease."

Heart failure is a serious and common condition in which the heart cannot pump enough blood through the body, leaving the patient debilitated and unable to conduct a normal life. It can result from heart attacks or a number of other causes. Patients suffering from the condition can experience shortness of breath and extreme exhaustion. It affects 20 million patients in Europe, US and Japan and this number is predicted to double by 2020. Therapies available for chronic heart failure aim at slowing down the disease progression, but with the exception of heart transplant, existing drugs or devices do not cure chronic heart failure.

Dr. Jozef Bartunek, Associate Director of the Cardiovascular Center in Aalst, Belgium and Co-Principal Investigator of the C-Cure trial commented: "C-Cure represents a major breakthrough in the field of cardiac regenerative medicine offering the potential of a curative treatment which could save lives and avoid the need for heart transplants. The trial is progressing very well and we look forward to seeing the safety data next year and to beginning the larger second stage to fully examine the efficacy of C-Cure for these patients."

About Cardio3 BioSciences

Cardio3 BioSciences is a leading Belgian biotechnology company specialising in stem cell-based therapies for the treatment of cardiovascular disease. The Company's lead product, C-Cure, is a highly innovative approach to the treatment of heart failure, one of the world's most pressing unmet medical needs. Based on a strategy developed by Cardio3 BioSciences' founders and leveraging technology from Mayo Clinic, C-Cure allows the differentiation of a patient's own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle.

The Cardio3 BioSciences team has extensive experience in developing and commercialising new pharmaceutical products and medical technologies and the Company's strategy is to drive the clinical development of C-Cure and to market the product itself in major territories.

Cardio3 BioSciences was founded in July 2007 and is based in Mont-Saint-Guibert in the Walloon region of Belgium.

Disclosures

Mayo Clinic has a financial interest in technology related to this research and may stand to gain from the successful outcome of the research. Mayo Clinic holds equity in Cardio3 BioSciences as a result of intellectual property licensed to the company.

    For more information contact:

    Cardio3 BioSciences:
    Dr Christian Homsy, CEO,
    Tel: +32-10-39-41-00,
    chomsy@c3bs.com .

    Mayra Beydoun, Brand & Communication Manager,
    Tel : +32-10-39-41-00,
    mbeydoun@c3bs.com .

    http://www.c3bs.com

    Citigate Dewe Rogerson:
    Chris Gardner/Nina Enegren,
    Tel : +44(0)207-638-9571,
    chris.gardner@citigatedr.co.uk .


SOURCE Cardio3 BioSciences


'/>"/>
SOURCE Cardio3 BioSciences
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cardio3 BioSciences Presents Update on C-Cure(R) Second Generation Stem Cell Therapy for Heart Failure at European Society of Cardiology Congress
2. Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia
3. YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT
4. YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES
5. Cell Biosciences Acquires Protein Forest
6. Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc.
7. Dow AgroSciences, Agrisoma Biosciences Announce Research and Commercial License Option Agreement for Agricultural Crops
8. Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference
9. YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA
10. American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor
11. Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... September 19, 2017 , ... A best-selling author ... tech companies. “Grit” author Angela Duckworth and her team at Character Lab have ... Cooley, an international law firm with decades of experience supporting high-growth companies in ...
(Date:9/19/2017)... ... 19, 2017 , ... The new and improved Oakton® pocket testers, from Cole-Parmer, ... upright with a new cap design that is versatile, functional and leakproof. They are ... to test water quality. , The Oakton pocket testers have many user-friendly and functional ...
(Date:9/19/2017)... , Sept. 19, 2017 ValGenesis Inc., the ... is pleased to announce the strategic partnership with VTI ... clients with validation services using the latest technology available ... will provide clients with efficient and cost-effective validation services ... partner for the ValGenesis VLMS system. ...
(Date:9/19/2017)... ... September 19, 2017 , ... Molecular Devices, ... with Cytena GmbH to launch the CloneSelect™ Single-Cell Printer™ in North America. ... single cells and provide visual documentation of monoclonality for use in cell line ...
Breaking Biology Technology:
(Date:4/13/2017)... PUNE, India , April 13, 2017 According ... Identity Proofing, Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication ... by MarketsandMarkets™, the IAM Market is expected to grow from USD 14.30 ... Annual Growth Rate (CAGR) of 17.3%. ... ...
(Date:4/11/2017)... Research and Markets has announced the addition of the "Global ... ... at a CAGR of 30.37% during the period 2017-2021. ... based on an in-depth market analysis with inputs from industry experts. ... the coming years. The report also includes a discussion of the ...
(Date:4/11/2017)... , April 11, 2017 NXT-ID, Inc. ... technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate governance ... Gino ... we look forward to their guidance and benefiting from their ...
Breaking Biology News(10 mins):